|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
CEO Designate
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
£16.9675
|
447.196
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016,
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
£16.9675
|
178.878
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S A Hussain
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
£16.9675
|
223.598
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr B McNamara
|
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 October 2016 on ADSs held
in the Company's Deferred Investment Award Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
$42.0900
|
284.061
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
£16.9675
|
178.878
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
Senior Vice President, Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
£16.9675
|
178.878
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description of
the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 October 2016
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
|
|
£16.9675
|
223.598
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
|
e)
|
Date
of the transaction
|
2016-10-13
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|